ReP USP - Resultado da busca

Artigo de periodico
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study (2023)
Barratt, Jonathan; Rovin, Brad; Wong, Muh Geot; Alpers, Charles E; Bieler, Stewart; He, Ping; Inrig, Jula; Komers, Radko; Heerspink, Hiddo J. L; Mercer, Alex; Noronha, Irene de Lourdes
Source: Kidney international reports. Unidade: FM
Subjects: NEFROPATIAS, PESQUISA QUALITATIVA, IMUNOGLOBULINAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BARRATT, Jonathan et al. IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study. Kidney international reports, v. 8, n. 5, p. 1043-1056, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/53820. Acesso em: 01 maio 2026.
APA
Barratt, J., Rovin, B., Wong, M. G., Alpers, C. E., Bieler, S., He, P., et al. (2023). IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study. Kidney international reports, 8( 5), 1043-1056. doi:10.1016/j.ekir.2023.02.1086
NLM
Barratt J, Rovin B, Wong MG, Alpers CE, Bieler S, He P, Inrig J, Komers R, Heerspink HJL, Mercer A, Noronha I de L. IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study [Internet]. Kidney international reports. 2023 ; 8( 5): 1043-1056.[citado 2026 maio 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/53820
Vancouver
Barratt J, Rovin B, Wong MG, Alpers CE, Bieler S, He P, Inrig J, Komers R, Heerspink HJL, Mercer A, Noronha I de L. IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study [Internet]. Kidney international reports. 2023 ; 8( 5): 1043-1056.[citado 2026 maio 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/53820
Artigo de periodico
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (2023)
Rovin, Brad H; Barratt, Jonathan; Heerspink, Hiddo J. L.; Alpers, Charles E.; Bieler, Stewart; Chae, Dong-Wan; Diva, Ulysses A.; Floege, Juergen; Gesualdo, Loreto; Inrig, Jula K.; Noronha, Irene de Lourdes
Source: LANCET. Unidade: FM
Subjects: ANGIOTENSINAS, GLOMERUNEFRITE, INSUFICIÊNCIA RENAL CRÔNICA, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROVIN, Brad H et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. LANCET, v. 402, n. 10417, p. 2077-2090, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/57858. Acesso em: 01 maio 2026.
APA
Rovin, B. H., Barratt, J., Heerspink, H. J. L., Alpers, C. E., Bieler, S., Chae, D. -W., et al. (2023). Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. LANCET, 402( 10417), 2077-2090. doi:10.1016/S0140-6736(23)02302-4
NLM
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae D-W, Diva UA, Floege J, Gesualdo L, Inrig JK, Noronha I de L. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial [Internet]. LANCET. 2023 ; 402( 10417): 2077-2090.[citado 2026 maio 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57858
Vancouver
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae D-W, Diva UA, Floege J, Gesualdo L, Inrig JK, Noronha I de L. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial [Internet]. LANCET. 2023 ; 402( 10417): 2077-2090.[citado 2026 maio 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57858
Artigo de periodico
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active- controlled clinical trial (2023)
Heerspink, Hiddo J. L; Radhakrishnan, Jai; Alpers, Charles E; Barratt, Jonathan; Bieler, Stewart; Diva, Ulysses; Inrig, Jula; Komers, Radko; Mercer, Alex; Noronha, Irene de Lourdes
Source: Lancet. Unidade: FM
Subjects: ALBUMINÚRIA, NEFROPATIAS, PROTEINÚRIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HEERSPINK, Hiddo J. L et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active- controlled clinical trial. Lancet, v. 401, n. 10388, p. 1584-1594, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/54593. Acesso em: 01 maio 2026.
APA
Heerspink, H. J. L., Radhakrishnan, J., Alpers, C. E., Barratt, J., Bieler, S., Diva, U., et al. (2023). Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active- controlled clinical trial. Lancet, 401( 10388), 1584-1594. doi:10.1016/S0140-6736(23)00569-X
NLM
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha I de L. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active- controlled clinical trial [Internet]. Lancet. 2023 ; 401( 10388): 1584-1594.[citado 2026 maio 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54593
Vancouver
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha I de L. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active- controlled clinical trial [Internet]. Lancet. 2023 ; 401( 10388): 1584-1594.[citado 2026 maio 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54593

USP Schools

ReP

Filtros

Authors

Subjects

Non normalized affiliation